|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Income | |||||
| Revenue | |||||
| Cost of revenue | |||||
| Gross Profit | |||||
| Selling, general and administrative | |||||
| Total | |||||
| Operating loss | |||||
| Total other (expense) income | |||||
| Interest expense | |||||
| Interest income | |||||
| Gain (loss) from investments in unconsolidated entities, net | |||||
| Loss from loans to unconsolidated entities | |||||
| Income (loss) from investments in unconsolidated entities, net | |||||
| Impairment expense - goodwill | |||||
| Total other expense | |||||
| Loss before income taxes | |||||
| Income tax benefit (provision) | |||||
| Net income (loss) | |||||
| Net loss attributable to noncontrolling interests | |||||
| Net loss | |||||
| Basic and diluted net loss per share attributable to Elite Health Systems Inc. (in dollars per share) | |||||
| Diluted net loss per share attributable to U.S. NeuroSurgical Holdings, Inc. (in dollars per share) | |||||
| Weighted average common shares outstanding, basic and diluted (in shares) | |||||
Loading...
